Status:
RECRUITING
Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants
Lead Sponsor:
Washington University School of Medicine
Conditions:
Nasal Obstruction
Chronic Rhinitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This prospective, virtually administered trial conducted throughout the United States aims to evaluate a standardized protocol including the serial dilution of topical decongestants with concurrent to...
Detailed Description
Participants will begin the trial by providing their average daily usage of oxymetazoline. They will then be stratified according to this usage and will be placed into a titration schedule. In the fir...
Eligibility Criteria
Inclusion
- 2\) have a history of chronic nasal obstruction 3) at least daily topical decongestant usage for at least 3 months 4) ability to read, write, and understand English.
Exclusion
- Any history of sinonasal mass/tumor
- Any history of nasal polyps
- Septal perforation
- A diagnosis of one of the following conditions:
- eosinophilic granulomatosis with polyangiitis
- granulomatosis with polyangiitis
- Any current intranasal drug use such as cocaine.
- If they are currently using or have used intranasal steroid medications (oral or nasal) besides oxymetazoline for the past month.
Key Trial Info
Start Date :
November 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07168148
Start Date
November 10 2025
End Date
December 1 2026
Last Update
November 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University
St Louis, Missouri, United States, 63110